source
- AstraZeneca’s oral GLP-1 candidate elecoglipron cuts weight 11% in Phase 2 obesity trialA Phase 2 study (VISTA) of AstraZeneca’s oral GLP‑1 molecule elecoglipron in people with obesity showed an average weight loss of 11.2 % after 36 weeks, according to data presented at the American…
- Treeline Biosciences to go public via reverse merger with Standard BioTools, securing runway to 2029Treeline Biosciences announced that it will become a publicly traded company through a reverse merger with Standard BioTools. The transaction is expected to list the combined entity on a U.S. excha…